Skip to content

Effect of Graston Technique on Planter Thickness in Patients With Planter Fasciitis

Effect of Graston Technique on Planter Thickness in Patients With Planter Fasciitis

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06248853
Acronym
PF
Enrollment
50
Registered
2024-02-08
Start date
2024-02-10
Completion date
2024-04-30
Last updated
2024-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plantar Fascitis

Keywords

graston technique, planter thickness, planter fasciitis

Brief summary

this study will be conducted to investigate the effect of Graston Technique on Planter Thickness in Patients With Planter Fasciitis

Detailed description

Plantar fasciitis (PF), generally a self-limiting condition, is identified as one of the most common causes of heel pain in adults. It affects both sedentary and athletic populations . It may be considered that PF emerges due to excessive and prolonged standing or running, which causes an acute inflammation or micro-tears, and degenerative changes plantar fascia. The persistence of these risk factors inhibits the regular repair process thus collagen degeneration occurs, causing the structural changes of the plantar fascia. Numerous interventions have been described for treatment of PF, which include: Stretching calf or plantar region which is performed with the patient stands with staggered legs facing toward a wall, with both hands stretched out .The Graston technique can break up scar tissue and restore soft tissue. The Graston technique is a type of manual therapy in which patented stainless-steel instruments are used to restore soft tissue motion by breaking up scar tissue. fifty patients with planter fasciitis will be assigned randomly to two equal groups; first one will receive graston technique in addition to exercise program, the second one will receive exercise program only for six weeks

Interventions

OTHERGarston technique

the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot

OTHERexercise program

the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

opaque sealed envelop

Intervention model description

Graston technique and exercise program

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* patients that Clinically diagnosed cases of plantar fasciitis not less than 6 weeks. * patients willing to precipitate in the study and take treatment for 6 successive weeks. * Heel pain felt maximally over the plantar aspect of heel * Pain in the heel on the first step in the morning * No history of rest pain in the heel

Exclusion criteria

* Subjects with clinical disorders where therapeutic ultrasound is contraindicated such as infective conditions of foot, tumor, calcaneal fracture, metal implant around ankle. * Subjects with a clinical disorder where myofascial release is contraindicated as dermatitis. * Subjects with impaired circulation to lower extremities * Subjects with referred pain due to sciatica and other neurological disorders. * Arthritis * Corticosteroids injection in heel preceding 3 months

Design outcomes

Primary

MeasureTime frameDescription
plantar thicknessup to six weeksUltrasonography will be used to measure planter thickness

Secondary

MeasureTime frameDescription
pain intensityup to six weeksVisual Analogue Scale (VAS) will be used to assess pain intensity: The VAS is a 100-mm horizontal line that may be used to quantify symptoms in a continuous fashion. Patients will instructed to indicate the intensity of their pain by marking on a line anchored by no pain on the left and worst imaginable pain on the right .
pain intensity at the first stepup to six weeksnumerical pain rating scale (NPRS) will be used to measure pain intensity at the first step. NPRS is a 10cm horizontal line t. Patients will instructed to indicate the intensity of their pain by marking on a line anchored by no pain on the left and worst imaginable pain on the right side.
functional levels of footup to six weeksThe Foot and Ankle Ability Measure (FAAM) questionnaire will be used to assess foot function. The FAAM is a self-reported questionnaire that comprehensively assesses the physical function of those with musculoskeletal conditions of the leg, foot, and ankle. It has a 21-item subscale for measuring the function of the individual with his or her activities of daily living (ADLs) and a ten-item subscale for measuring function with sports. The ADL subscale will be used for this study. The instrument is scored on a Likert scale from 4 to 0, with 4 representing ''no difficulty'' as going up stairs and 0 representing ''unable to do.'' The answers are then converted to a scale from 0 to 100, with a higher score representing a higher functional level.
pain pressure thresholdup to six weeksThe pressure algometer device will be used to measure pain pressure threshold

Contacts

Primary Contactmostafa elshenawy, master
melshenawy584@gmail.com01124009013
Backup Contactmohamed elgendy, professor
prof.mgendy@hotmail.com01005747169

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026